Sometimes it is worth it to buy shares of companies on the dip, and sometimes it isn't. It all depends on whether there are good reasons to believe the company in question will bounce back, and if it will, there is arguably no better time to invest than when it is down. Thankfully, even in a bull market like the one we're experiencing, you can find beaten-down but otherwise exciting stocks to buy. However, other market laggards are better left alone. Let's consider one stock in each category: Teladoc Health ...

GAITHERSBURG, Md., April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19- Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress 2024 (WVC) in Washington, DC, April 2 to 4, 2024. New data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in ...

Investing basics tell us to "buy low" and invest in a stock when there looks to be significant upside potential. That can often be after a company gets put through the wringer and the stock declines substantially. However, sometimes it's not worth investing in a company no matter how much its shares fall. Case in point: Novavax (NVAX -2.85%) is a biotech stock down by 97% over the past three years, yet the stock still doesn't look attractive. Read on to find out why. Novavax's coronavirus efforts fell short ...

A bull market is here, but not every stock is benefiting. Some players remain in the doldrums. It's up to investors to decide whether those left behind are likely to remain there or make top buying opportunities today that could deliver great rewards down the road. Wall Street is particularly enthusiastic about two beaten-down biotech stocks that soared in the earlier days of the pandemic. These two developed coronavirus vaccine candidates, and investors were betting they could eventually commercialize the ...

业绩总结 - 公司在2022年底的支出基础为17亿美元[56] - 第一季度已经有1亿美元的APA收入，其中欧洲APA已经结束[24] - 预计到2026年，APA将全部转为商业市场，推出第二款流感疫苗[30] - 预计今年秋季在商业市场推出COVID疫苗[51] 用户数据 - 公司在非美国市场和美国市场有着极高的关注度，特别是在零售方面[57] - 公司计划在2024年推出预填充注射器，以取代五剂瓶，预计将有更广泛的覆盖范围[7] - 公司在非美国市场和美国市场有着极高的关注度，特别是在零售方面，学习到了不需要在非零售领域投资[57] 未来展望 - 公司预计在2024年实现8亿至10亿美元的收入，其中大部分来自海外的预购协议，同时计划在美国和欧洲等地推出商业市场[23] - 预计今年秋季在商业市场推出COVID疫苗[51] - 第三阶段研究计划于今年下半年开始，预计2025年上市[31] 新产品和新技术研发 - 公司计划通过供应链优化节省约1亿美元，包括考虑出售CZ工厂，以及在销售、一般行政和研发方面节省2亿美元或更多[56] - 新疫苗将采用一支预填充注射器或两支注射器[33] - 通过成功的成本削减，公司有能力独立进行第三阶段研究[40] 市场扩张和并购 - 公司目前生产的疫苗针对 JN.1 变种效果良好，预计将在未来的变种中保持有效性[18] - 公司在非美国市场和美国市场有着极高的关注度，特别是在零售方面，学习到了不需要在非零售领域投资，只需要适当扩展[57] - 与Bill和Melinda Gates基金会签署技术协议，继续合作[47]

Novavax (NVAX 9.11%) has taken investors on a roller coaster ride over the past week or so. The stock soared after the company settled a dispute with a big customer, then sank as it reported lower-than-expected earnings. The vaccine maker has struggled to win over the investment community after entering the coronavirus vaccine market late with its initial vaccine -- and commercializing its updated vaccine after rivals this past fall. The initial late entry meant Novavax missed out on the biggest revenue opp ...

Since 2021, shares of Novavax (NVAX 12.02%) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the past few years. The price drop was justified largely because the company's fate was uncertain. There were question marks relating to its growth and a canceled purchase agreement. The good news is that one of those issues recently reached a positive resolution. Is that enough to make this beaten-down stock worth ta ...

GAITHERSBURG, Md., Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, March 6, 2024 Time: 1:30 – 2:00 p.m. Eastern Standard Time (EST) Location: Boston Marriott Copley Place in Boston, Massachusetts Moderator: Brendan Smith, Ph.D., Vice President, Biotechnology Equity Research Novavax p ...

财务表现 - Novavax公司2023年第四季度每股亏损为1.44美元，远远高于Zacks Consensus Estimate的每股亏损49美分[1] - 该季度营收为2.913亿美元，也低于Zacks Consensus Estimate的3.34亿美元，同比下降18.5%[2] - 产品销售额为2.514亿美元，同比下降12.6%，超过了模型预估的2.465亿美元，而赠款收入同比下降45.4%至3.79百万美元[3] - Novavax从特许合作伙伴的版税和佐剂销售中获得了190万美元的收入，而去年同期仅为40万美元[4] - 研发费用为1.65亿美元，同比减少近36%，销售、一般和管理费用同比减少4.3%至1.55亿美元[5] 资金状况 - 截至2023年12月31日，Novavax的现金及现金等价物为5.84亿美元，较9月30日的6.66亿美元有所下降[6] 市场表现 - Novavax股价在2月28日下跌了26.7%，过去一年下跌了36.9%[7] 年度业绩 - 2023年，Novavax的营收为9.837亿美元，较2022年的19亿美元有所下降[8] - 2023年，Novavax每股亏损5.41美元，较2022年的8.42美元有所减少，公司预计2024年总营收在8亿至10亿美元之间[9] 未来计划 - Novavax计划在2024年下半年开始进行其新冠疫苗和流感疫苗的关键三期研究，计划在2026年商业化[14]

Proactive新闻团队 - Josh Lamb于2022年毕业于肯特大学历史专业，后加入Proactive担任英国编辑团队的记者[1] - Proactive的新闻团队遍布全球主要金融和投资中心，设有办事处和工作室[2] Proactive的关注领域 - Proactive专注于中小市值市场，同时也关注蓝筹公司、大宗商品和更广泛的投资故事，旨在激发和吸引有动力的个人投资者[3] - Proactive团队提供市场上跨领域的新闻和独特见解，涵盖生物技术和制药、矿业和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术等领域[4]